Read More Pharma Industry News Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025 Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape. bySrinathDecember 2, 2025